Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid

Biochemical and Biophysical Research Communications

Volumn 366, Issue 1, 2008, Pages 110-116

  Matsumoto, Yohsuke ^a   Motoki, Takahiro ^a   Kubota, Satoshi ^a   Takigawa, Masaharu ^a   Tsubouchi, Hirohito ^b   Gohda, Eiichi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Butyric acid; Dermal fibroblast; Hepatocyte growth factor; Histone deacetylase inhibitor; Induction; Trichostatin A; Tumor invasion; Valproic acid

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BUTYRIC ACID; EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; PHORBOL 12 ACETATE 13 MYRISTATE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROSTAGLANDIN E2; SCATTER FACTOR; TRICHOSTATIN A; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL INTERACTION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FIBROBLAST CULTURE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; STROMA; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL COMMUNICATION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; STROMAL CELLS; VALPROIC ACID;

EID: 37349128547     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.11.089     Document Type: Article

References (37)

1. Michalopoulos G., Cianciulli H.D., Novotny A.R., Kligerman A.D., Strom S.C., and Jirtle R.L. Liver regeneration studies with rat hepatocytes in primary culture. Cancer Res. 42 (1982) 4673-4682
2. Gohda E., Tsubouchi H., Nakayama H., Hirono S., Sakiyama O., Takahashi K., Miyazaki H., Hashimoto S., and Daikuhara Y. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J. Clin. Invest. 81 (1988) 414-419
3. Nakamura T., Nawa K., Ichihara A., Kaise N., and Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett. 224 (1987) 311-316
4. Miyazawa K., Tsubouchi H., Naka D., Takahashi K., Okigaki M., Arakaki N., Nakayama H., Hirono S., Sakiyama O., Takahashi K., Gohda E., Daikuhara Y., and Kitamura N. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163 (1989) 967-973
5. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., Tashiro K., and Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 342 (1989) 440-443
6. Zarnegar R., and Michalopoulos G.K. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J. Cell Biol. 129 (1995) 1177-1180
7. Matsumoto K., and Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem. Biophys. Res. Commun. 239 (1997) 639-644
8. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., and Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373 (1995) 699-702
9. Uehara Y., Minowa O., Mori C., Shiota K., Kuno J., Noda T., and Kitamura N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373 (1995) 702-705
10. Huh C.G., Factor V.M., Sánchez A., Uchida K., Conner E.A., and Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA 101 (2004) 4477-4482
11. Phaneuf D., Moscioni A.D., LeClair C., Raper S.E., and Wilson J.M. Generation of a mouse expressing a conditional knockout of the hepatocyte growth factor gene: demonstration of impaired liver regeneration. DNA Cell Biol. 23 (2004) 592-603
12. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nature Rev. Mol. Cell Biol. 4 (2003) 915-925
13. Gao C.F., and Vande Woude G.F. HGF/SF-Met signaling in tumor progression. Cell Res. 15 (2005) 49-51
14. Jiang W.G., Hiscox S., Matsumoto K., and Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol. 29 (1999) 209-248
15. Junbo H., Li Q., Zaide W., and Yunde H. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. In vivo 13 (1999) 177-180
16. Cress W.D., and Seto E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184 (2000) 1-16
17. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
18. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
19. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
20. Matsunaga T., Gohda E., Takebe T., Wu Y.L., Iwao M., Kataoka H., and Yamamoto I. Expression of hepatocyte growth factor is up-regulated through activation of a cAMP-mediated pathway. Exp. Cell Res. 210 (1994) 326-335
21. Tsubouchi H., Niitani Y., Hirono S., Nakayama H., Gohda E., Arakaki N., Sakiyama O., Takahashi K., Kimoto M., Kawakami S., Setoguchi M., Tachikawa T., Shin S., Arima T., and Daikuhara Y. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology 13 (1991) 1-5
22. Takami Y., Kanasaki K., Tsubouchi H., Ishii T., Yamamoto I., and Gohda E. Inhibition of hepatocyte growth factor induction in human dermal fibroblasts by interleukin-1 and its prevention by interferon-γ. Biochem. Biophys. Res. Commun. 325 (2004) 676-682
23. Gohda E., Okauchi H., Iwao M., and Yamamoto I. Induction of apoptosis by hepatocyte growth factor/scatter factor and its augmentation by phorbol esters in Meth A cells. Biochem. Biophys. Res. Commun. 245 (1998) 278-283
24. Takami Y., Yamamoto I., Tsubouchi H., and Gohda E. Modulation of hepatocyte growth factor induction in human skin fibroblasts by retinoic acid. Biochim. Biophys. Acta 1743 (2005) 49-56
25. Ide T., Kitajima Y., Miyoshi A., Ohtsuka T., Mitsuno M., Ohtaka K., Koga Y., and Miyazaki K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int. J. Cancer 119 (2006) 2750-2759
26. Gohda E., Matsunaga T., Kataoka H., Takebe T., and Yamamoto I. Induction of hepatocyte growth factor in human skin fibroblasts by epidermal growth factor, platelet-derived growth factor and fibroblast growth factor. Cytokine 6 (1994) 633-640
27. Tamura M., Arakaki N., Tsubouchi H., Takada H., and Daikuhara Y. Enhancement of human hepatocyte growth factor production by interleukin-1α and -1β and tumor necrosis factor-α by fibroblasts in culture. J. Biol. Chem. 268 (1993) 8140-8145
28. Reid G., Métivier R., Lin C.Y., Denger S., Ibberson D., Ivacevic T., Brand H., Benes V., Liu E.T., and Gannon F. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor α, in response to deacetylase inhibition by valpronic acid and trichostatin A. Oncogene 24 (2005) 4894-4907
29. Neaud V., Faouzi S., Guirouilh J., Bail B.L., Balabaud C., Bioulac-Sage P., and Rosenbaum J. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 26 (1997) 1458-1466
30. Abiru S., Nakao K., Ichikawa T., Migita K., Shigeno M., Sakamoto M., Ishikawa H., Hamasaki K., Nakata K., and Eguchi K. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35 (2002) 1117-1124
31. Lee W.J., Wu L.F., Chen W.K., Wang C.J., and Tseng T.H. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem. Biol. Interact. 160 (2006) 123-133
32. Matsumoto K., and Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 119 (2006) 477-483
33. Christensen J.G., Burrows J., and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225 (2005) 1-26
34. Cantello R., Civardi C., Varrasi C., Vicentini R., Cecchin M., Boccagni C., and Monaco F. Excitability of the human epileptic cortex after chronic valproate: a reappraisal. Brain Res. 1099 (2006) 160-166
35. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 389 (1997) 349-352
36. Woodhouse E.C., Chuaqui R.F., and Liotta L.A. General mechanisms of metastasis. Cancer 80 (1997) 1529-1537
37. Royal I., and Park M. Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. J. Biol. Chem. 270 (1995) 27780-27787